Table 1.
Sociodemographic and clinical characteristics
| 1A. Preoperative (N = 166) | 1B. Postoperative (N = 146) | 2A. Tumor grade II (N = 120) | 2B. Tumor grades III and IV (N = 136) | 3A. Non-fatigued (N = 117) | 3B. Fatigued (N = 174) | |
|---|---|---|---|---|---|---|
| Age, mean (SD) | 45.9 (14.1) | 44.7 (12.1) | 41.5 (11.7) | 50.9 (13.4) | 45.1 (13.6) | 46.8 (13.2) |
| Sex, n (%) | ||||||
| Male | 103 (62.0%) | 89 (61.0%) | 68 (56.7%) | 92 (67.6%) | 83 (70.9%) | 99 (56.9%) |
| Female | 63 (38.0%) | 57 (39.0%) | 52 (43.3%) | 44 (32.4%) | 34 (29.1%) | 75 (43.1%) |
| Tumor hemisphere, n (%) | ||||||
| Left | 101 (60.8%) | 82 (56.2%) | 69 (57.5%) | 77 (56.6%) | 76 (65.0%) | 89 (51.1%) |
| Right | 61 (36.7%) | 60 (41.1%) | 47 (39.2%) | 54 (39.7%) | 39 (33.3%) | 77 (44.3%) |
| Both | 4 (2.4%) | 4 (2.7%) | 4 (3.3%) | 5 (3.7%) | 2 (1.7%) | 8 (4.6%) |
| Tumor grade and histology, n (%) | ||||||
| II astrocytoma | 42 (25.3%) | 45 (30.8%) | 65 (54.2%) | 0 (0%) | 36 (30.8%) | 42 (24.1%) |
| II oligoastrocytoma* | 13 (7.8%) | 11 (7.5%) | 16 (13.3%) | 0 (0%) | 5 (4.3%) | 12 (6.9%) |
| II oligodendroglioma | 24 (14.5%) | 29 (19.9%) | 39 (32.5%) | 0 (0%) | 18 (15.4%) | 27 (15.5%) |
| III astrocytoma | 13 (7.8%) | 10 (6.8%) | 0 (0%) | 21 (15.4%) | 9 (7.7%) | 16 (9.2%) |
| III oligoastrocytoma* | 4 (2.4%) | 3 (2.1%) | 0 (0%) | 6 (4.4%) | 4 (3.4%) | 3 (1.7%) |
| III oligodendroglioma | 24 (14.5%) | 21 (14.4%) | 0 (0%) | 36 (26.5%) | 14 (12.0%) | 27 (15.5%) |
| IV glioblastoma | 46 (27.7%) | 27 (18.5%) | 0 (0%) | 73 (53.7%) | 31 (26.5%) | 47 (27.0%) |
| IDH status, n (%) | ||||||
| IDH wildtype | 36 (21.7%) | 12 (8.2%) | 9 (7.5%) | 38 (27.9%) | 18 (15.4%) | 31 (17.8%) |
| IDH mutant | 72 (43.4%) | 71 (48.6%) | 77 (64.2%) | 31 (22.8%) | 56 (47.9%) | 72 (41.4%) |
| Unknown | 58 (34.9%) | 63 (43.2%) | 34 (28.3%) | 67 (49.3%) | 43 (36.8%) | 71 (40.8%) |
| Disease status, n (%) | ||||||
| Preoperative | 166 (100%) | 0 (0%) | 62 (51.7%) | 76 (55.9%) | 56 (47.9%) | 91 (52.3%) |
| On active treatment | 0 (0%) | 68 (46.6%) | 24 (20.0%) | 29 (21.3%) | 25 (21.4%) | 39 (22.4%) |
| Stable^ | 0 (0%) | 78 (53.4%) | 30 (25.0%) | 20 (14.7%) | 29 (24.8%) | 34 (19.5%) |
| Progression | 0 (0%) | 0 (0%) | 4 (3.3%) | 11 (8.1%) | 7 (6.0%) | 10 (5.7%) |
*Histological diagnosis of these patients was based on the older 2007 WHO classification of central nervous system tumors [40]
^Stable disease was defined as no radiological or clinical progression and no anti-tumor therapy at least 3 months prior to the assessment